Literature DB >> 17266396

New observations on bone quality in mild primary hyperparathyroidism as determined by quantitative backscattered electron imaging.

Paul Roschger1, David W Dempster, Hua Zhou, Eleftherios P Paschalis, Shonni J Silverberg, Elisabeth Shane, John P Bilezikian, Klaus Klaushofer.   

Abstract

UNLABELLED: Bone mineralization density distribution, an important aspect of bone material quality, was determined in mild primary hyperparathyroidism using quantitative backscattered electron imaging. A strong correlation between bone turnover status and degree and heterogeneity of mineralization was found. Further studies are needed before we can draw conclusions about fracture risk in this disorder.
INTRODUCTION: Mild primary hyperparathyroidism (PHPT) is best characterized by asymptomatic hypercalcemia, most commonly in the absence of classical signs and symptoms. Hence, there is need to characterize this disorder with particular attention to the skeleton.
MATERIALS AND METHODS: We analyzed bone mineralization density distribution (BMDD) in iliac crest bone biopsies from patients with PHPT in 51 subjects (16 men, 28-68 years of age; 35 women, 26-74 years of age) by quantitative backscattered electron imaging (qBEI). The BMDD variables quantified are as follows: Ca(MEAN), the weighted mean calcium concentration; Ca(PEAK), the most frequent Ca concentration; Ca(WIDTH), the width of the distribution, a measure of the mineralization homogeneity; Ca(LOW), the percentage of bone area that is mineralized below the fifth percentile in the reference range. The results were compared with a reference range that we have previously established.
RESULTS: The greatest differences were found in Ca(WIDTH) (+15.7%, p<0.0001) and Ca(LOW) (+44.7%, p<0001), both of which were significantly higher in PHPT than control. Ca(MEAN) was significantly lower (-2.5%, p<0.0001) in PHPT compared with controls. These differences were reversed in seven patients who underwent parathyroidectomy. Ca(MEAN) and Ca(PEAK) variables were negatively, whereas Ca(WIDTH) and Ca(LOW) were positively, correlated with dynamic variables of bone formation: mineralizing surface and bone formation rate as determined by histomorphometry. (r = +/-0.3-0.8; p=0.05-0.0001). These results, which represent the first BMDD measurements in mild PHPT using qBEI, show a reduction in the average mineralization density and an increase in the heterogeneity of the degree of mineralization. These changes correlate significantly with the bone turnover rate.
CONCLUSIONS: The results are consistent with our previous observations of increased bone turnover in this disease, and consequently, reduced mean age of bone tissue. Reduced mineralization density in patients with PHPT would be expected to reduce the stiffness of bone tissue. These observations are relevant to considerations of fracture risk in PHPT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17266396     DOI: 10.1359/jbmr.070120

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  20 in total

1.  Bone matrix mineralization is preserved during early perimenopausal stage in healthy women: a paired biopsy study.

Authors:  B M Misof; P Roschger; S Blouin; R Recker; K Klaushofer
Journal:  Osteoporos Int       Date:  2015-12-09       Impact factor: 4.507

Review 2.  Bone mineralization: from tissue to crystal in normal and pathological contexts.

Authors:  Y Bala; D Farlay; G Boivin
Journal:  Osteoporos Int       Date:  2012-12-11       Impact factor: 4.507

3.  Bone disease in primary hyperparathyrodism.

Authors:  Claudio Marcocci; Luisella Cianferotti; Filomena Cetani
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-10       Impact factor: 5.346

4.  Specimen size and porosity can introduce error into microCT-based tissue mineral density measurements.

Authors:  Roberto J Fajardo; Esther Cory; Nipun D Patel; Ara Nazarian; Andres Laib; Rajaram K Manoharan; James E Schmitz; Jeremy M DeSilva; Laura M MacLatchy; Brian D Snyder; Mary L Bouxsein
Journal:  Bone       Date:  2008-09-10       Impact factor: 4.398

5.  Spectroscopic markers of bone quality in alendronate-treated postmenopausal women.

Authors:  A L Boskey; L Spevak; R S Weinstein
Journal:  Osteoporos Int       Date:  2008-09-04       Impact factor: 4.507

6.  Bone mineralization is elevated and less heterogeneous in adults with type 2 diabetes and osteoarthritis compared to controls with osteoarthritis alone.

Authors:  J M Pritchard; A Papaioannou; C Tomowich; L M Giangregorio; S A Atkinson; K A Beattie; J D Adachi; J DeBeer; M Winemaker; V Avram; H P Schwarcz
Journal:  Bone       Date:  2013-01-26       Impact factor: 4.398

7.  Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism.

Authors:  Edda Vignali; Giuseppe Viccica; Daniele Diacinti; Filomena Cetani; Luisella Cianferotti; Elena Ambrogini; Chiara Banti; Romano Del Fiacco; John P Bilezikian; Aldo Pinchera; Claudio Marcocci
Journal:  J Clin Endocrinol Metab       Date:  2009-04-28       Impact factor: 5.958

8.  Bone quality determined by Fourier transform infrared imaging analysis in mild primary hyperparathyroidism.

Authors:  Ruth Zoehrer; David W Dempster; John P Bilezikian; Hua Zhou; Shonni J Silverberg; Elizabeth Shane; Paul Roschger; Eleftherios P Paschalis; Klaus Klaushofer
Journal:  J Clin Endocrinol Metab       Date:  2008-07-01       Impact factor: 5.958

9.  The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years.

Authors:  Mishaela R Rubin; John P Bilezikian; Donald J McMahon; Thomas Jacobs; Elizabeth Shane; Ethel Siris; Julia Udesky; Shonni J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2008-06-10       Impact factor: 5.958

10.  Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.

Authors:  Shonni J Silverberg; Bart L Clarke; Munro Peacock; Francisco Bandeira; Stephanie Boutroy; Natalie E Cusano; David Dempster; E Michael Lewiecki; Jian-Min Liu; Salvatore Minisola; Lars Rejnmark; Barbara C Silva; Marcella D Walker; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2014-08-27       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.